Literature DB >> 25907701

Therapy: Facing up to biosimilar agents--the ACR position.

Morton Scheinberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25907701     DOI： 10.1038/nrrheum.2015.57

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  8 in total

Review 1.  When biotech proteins go off-patent.

Authors:  H Schellekens
Journal:  Trends Biotechnol       Date:  2004-08       Impact factor: 19.536

Review 2.  The advent of biosimilar therapies in rheumatology--"O brave new world".

Authors:  Morton A Scheinberg; Jonathan Kay
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

3.  Biosimilars in Crohn's disease.

Authors:  Morton Scheinberg
Journal:  J Crohns Colitis       Date:  2013-12-22       Impact factor: 9.071

Review 4.  Biologic therapies in rheumatology: lessons learned, future directions.

Authors:  Vibeke Strand; Robert Kimberly; John D Isaacs
Journal:  Nat Rev Drug Discov       Date:  2007-01       Impact factor: 84.694

5.  Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor.

Authors:  Axel Finckh
Journal:  J Comp Eff Res       Date:  2012-11       Impact factor: 1.744

6.  Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.

Authors:  Michael H Schiff; Johannes von Kempis; Ronald Goldblum; John R Tesser; Ruediger B Mueller
Journal:  Ann Rheum Dis       Date:  2014-06-27       Impact factor: 19.103

Review 7.  Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.

Authors:  Morton Scheinberg; Gilberto Castañeda-Hernández
Journal:  Arthritis Res Ther       Date:  2014-12-06       Impact factor: 5.156

8.  Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2013-07-24       Impact factor: 5.857
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.